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Non-standard Abbreviations: 
PGHS  Prostaglandin G/H synthase 
PLA2  Phospholipase A2 
sPLA2  Secretory phospholipase A2 
cPLA2  Cytosolic phospholipase A2 
iPLA2  Calcium independent phospholipase A2 
AA  Arachidonic acid 
BMD  Bone mineral density 
PTH  Parathyroid hormone 
PAF  Platelet activating factor 
OVX  Ovariectomy/ovariectomized 
SHAM  Sham operated 
DFU  [5,5-dimethyl-3-3 (3 fluorophenyl)-4-(4 methylsulphonal) phenyl-2 (5H)-furanone] 
KH064 [5-(4-benzyloxyphenyl)-4S-(7-phenylheptanoylamino-pentanoic acid)] 
PEG  Polyethylene glycol 
NBF  Neutral buffered formalin 
TRAP  tartrate resistant acid phosphatase 
PLC  Phospholipase C 
PLD  Phospholipase D 
ET-1  Endothelin-1 
T1  Timepoint 1: 72 days 
T2  Timepoint 2: 98 days 
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ABSTRACT 
 
Accelerated states of osteoblast and osteoclast activity are regulated by prostaglandins in vitro, but 
experimental evidence for specific roles of cyclooxygenase-2 (COX-2) and secretory phospholipase 
A2 (sPLA2) in bone adaptive remodeling in vivo is lacking. We found that treatment with a specific 
COX-2 or sPLA2 (group IIa) inhibitor prevented ovariectomy-induced (OVX-induced) decreases in 
trabecular connectivity; suppressed the acceleration of bone resorption; and maintained bone 
turnover at SHAM levels following OVX in the rat. The sPLA2 inhibitor significantly suppressed 
increases in osteoclast surface induced by OVX, whilst the COX-2 inhibitor only had a marginal 
effect. These findings demonstrate that specific inhibitors of COX-2 and sPLA2-IIa effectively 
suppress OVX-induced bone loss in the adult rat by conserving trabecular bone mass and 
architecture through reduced bone remodeling and decreased resorptive activity. Moreover we 
report an important role of sPLA2-IIa in osteoclastogenesis independent of the COX-2 metabolic 
pathway in the OVX rat in vivo. 
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INTRODUCTION 
Prostaglandins are essential mediators of bone formation and resorption allowing the 
initiation of bone adaptive changes in response to mechanical (1, 2) or endocrine signals (3). Two 
major enzyme classes in PG synthesis are phospholipases A2 (PLA2), which release arachidonic 
acid (AA) from membrane fatty acids, and prostaglandin G/H synthases (PGHS), or 
cyclooxygenases (COX), which oxidize AA to PGG2 and reduce PGG2 to PGH2 (4). Arachidonic 
acid acts as the substrate for both prostaglandins and leukotrienes, via COX and 5-lipoxygenase 
activities, respectively. 5-lipoxygenase metabolites increase production during inflammation and 
stimulate resorption in vitro and in vivo (5). The availability of AA is essential for these metabolic 
pathways and is dependent on the activity of PLA2 enzymes on glycerophospholipid membranes. 
Three main classes of PLA2 have been isolated: cytosolic (cPLA2), calcium independent (iPLA2) 
and a secretory (sPLA2) form. Cells and tissues extracted from cPLA2-deficient mice fail to produce 
leukotrienes, prostaglandins and platelet activating factor (PAF) ex vivo (6), emphasizing the 
importance of PLA2 activity in the production of glycerophospholipid metabolites. A role for PLA2 
enzymes in regulating bone function has been suggested in cell and organ culture studies (7-15), but 
in vivo work is limited. 
Prostaglandins are rapidly removed and degraded in vivo, necessitating auto-amplification to 
produce a sustained PG response (16). Cytosolic PLA2 is an arachidonyl-selective phospholipase 
and is the main regulatory phospholipase that modulates cellular AA release and PGE2 production 
in osteoblasts (17). Secretory PLA2 enzymes show little preference for AA, hydrolyzing other more 
abundant fatty acids such as oleic acid and linoleic acid (13). By binding to specific receptors on 
osteoblasts, however, sPLA2 enzymes indirectly increase the release of AA via cPLA2 activity (12). 
In this way, sPLA2 acts as an important auto- and trans-cellular amplifier of eicosanoid production 
(18). Inhibition of osteoblastic and osteocytic sPLA2 activity abolishes loading-related increases in 
PGE2 and PGI2 secretion ex vivo (9), whereas inhibition of cPLA2 prevents loading-induced release 
of PGE2 but not PGI2 (9). This suggests that sPLA2 can act independently, whilst also augmenting 
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the activity of cPLA2. Its role may therefore be cell- and agonist-specific, acting through a capacity 
to attach to cell surface binding proteins in addition to its hydrolyzing activity (12).  With multiple 
phospholipases A2 available to liberate AA for eicosanoid production, the importance of sPLA2-IIa, 
the principal sPLA2 found in synovial joints of arthritis sufferers, in the bone microenvironment has 
not been extensively investigated. 
Two COX isoforms have been identified in human tissues, the regulatory COX-1 enzyme 
and the inducible COX-2, both of which act on AA to synthesize prostaglandins. Studies utilizing 
specific COX-2 inhibitors, or COX-2 deficient mice, demonstrate the importance of COX-2 in 
inflammatory events (19, 20) and in accelerated states of bone formation and resorption (1, 2, 21-
23). For example, blockade of COX-2 activity can retard bone adaptation, preventing loading-
induced bone formation (1, 2); or delay healing in bone fractures (21-23). Bone resorption induced 
by IL-1 and IL-6 also occurs via stimulation of COX-2 dependent PGE2 production in osteoblasts, 
acting to increase osteoclastogenesis (24, 25). This COX-2 specific regulation of resorption is not 
necessary for wild-type bone development, but plays a critical role in activated states of bone 
resorption, such as those stimulated by vitamin D and PTH (3). In the latter case, treatment with 
propionate-based NSAIDs is associated with higher bone mineral density (BMD) in women aged 
between 44 and 85. These positive changes are independent of lifestyle, medication factors, and 
degree of osteoarthritis (26). Although the reasons for the greater BMD have not been established, 
they are consistent with maintenance of trabecular bone architecture observed in ovariectomized 
rats treated with the non-selective COX-2 inhibitor, Naproxen (27). The specific role of COX-2 in 
mediating activated states of bone remodeling in vivo has not been investigated and requires further 
scrutiny. 
 Here we show that specific inhibitors of sPLA2-IIa and COX-2 effectively inhibited OVX-
induced bone loss in rats by conserving trabecular bone mass and architecture through reduced bone 
remodeling and decreased resorptive activity. These in vivo data support epidemiological evidence 
for a bone sparing effect of COX-2 inhibitors in postmenopausal women. Moreover, the inhibitor of 
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sPLA2-IIa significantly prevented OVX-induced rises in osteoclast number, suggesting an important 
role for sPLA2-IIa in osteoclastogenesis, independent of the COX-2 metabolic pathway. This sPLA2 
may therefore play a central role in the amplification of PG synthesis associated with osteoclast 
differentiation. 
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MATERIALS & METHODS 
Ovariectomy 
One hundred and twenty-four female Wistar rats (385 ± 52 g) were anaesthetized using ketamine 
(Parnell, 60mg/kg i.p.) and xylazil-20 (Ilium, 30mg/kg i.p.), and bilaterally ovariectomized (OVX) 
or SHAM-operated (SHAM) at an age ranging between 8 and 9 months. The SHAM-operation 
involved the exposure of the ovaries without full extraction, leaving the ovaries intact, whilst OVX 
rats underwent full removal of both the right and left ovaries. The University of Queensland Animal 
Ethics Committee approved all experiments. 
Housing 
Removal of the ovaries is accompanied by an increase in body mass in the rat. So that the extra load 
did not suppress bone loss, food consumption was restricted by giving all rats 18g of standard 
laboratory pellets per day, commencing a few days before surgery [Howard Morris, Personal 
Communication; (27)]. Any food remaining the next day was discarded and replaced with a new 
amount of weighed food. Rats were caged in pairs and had constant access to water. Temperature 
was maintained between 18˚C and 23˚C, and a diurnal light control allowed daily light and dark 
periods of 12 hours each.  
Drug Administration 
Eight rats were euthanized prior to surgery as a baseline control group, and 8 rats were euthanized 
two weeks post-OVX as an OVX-control group. The remainder commenced treatment 14 days after 
surgery with either Vehicle (VEH), a selective COX-2 inhibitor (DFU [5,5-dimethyl-3-3 (3 
fluorophenyl)-4-(4 methylsulphonal) phenyl-2 (5H)-furanone], Merck, Sharpe and Dohme, USA) at 
0.02 mg.kg.d-2 and 2.0 mg.kg.d-2; or a sPLA2-IIa inhibitor (KH064, [5-(4-benzyloxyphenyl)-4S-(7-
phenylheptanoylamino-pentanoic acid)], University of Queensland) at 0.4 mg.kg.d-2 and 4.0 
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mg.kg.d-2. DFU inhibits the arachidonic acid-dependent production of PGE2 in CHO cells with at 
least 1,000 fold selectivity for COX-2 (IC50 = 41+14 nM) over COX-1 (IC50 > 50 μM) (28). KH064 
is two-fold more potent against the group sPLA2-IIa human enzyme [IC50 29nM; (29)] than a 
previously published inhibitor (LY311299), but 170-fold more selective for the group IIa isoform 
over the group V human sPLA2 enzyme (30), and does not bind to human cPLA2. It also does not 
bind to some 30 receptors and enzymes screened by MDS Pharma Services (Fairlie, unpublished). 
We consider that KH064 is a selective inhibitor of human sPLA2-IIa (31). Polyethylene glycol 
(PEG) was used as the vehicle treatment and both DFU and KH064 were prepared in PEG. At the 
start of the treatment period, DFU was administered i.p. and KH064 by oral gavage. One month 
after commencement of treatment, all rats were treated by oral gavage in the interests of animal 
welfare. This was to avoid potential adverse effects of prolonged i.p injections. Treatment 
continued daily until rats were euthanized by CO2 inhalation at 70 days (T1) or 98 days (T2) post-
OVX.  
 For dynamic histomorphometry, fluorescent labels (Calcein 7.0 mg.kg-1 i.p.; Sigma 
Chemical Co, St Louis MO) were administered 7 and 2 days before euthanasia. At euthanasia the 
uterus was removed to verify the success of OVX.  
Tissue Processing 
The right and left tibiae were extracted and stored in 10% neutral buffered formalin (NBF) for 
structural and cellular histomorphometry, respectively. Right tibiae were sectioned transversely, 13 
mm distal to the proximal epiphysis and were fixed in cold NBF (10%) for 24 hours. Tibiae were 
then washed in 70% ethanol and embedded in methylmethacrylate for structural bone analysis. Left 
tibiae were similarly cut and fixed, but then decalcified using a series of EDTA washes. Once 
decalcification was confirmed by x-ray, tibiae were embedded in paraffin and sectioned for cellular 
histomorphometry.  
Structural Histomorphometry 
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Thick sections (70 – 100 µm) were cut from right tibiae with a diamond-blade microtome (Leitz 
1600 Saw Microtome, Leica, Wetzlar) and mounted unstained on glass slides for light and 
fluorescence microscopy using an Olympus BX-60 Fluorescence microscope, at magnification of X 
400. The microscope was connected to a Macintosh computer via a digitizing tablet (Calcomp 
Drawing Slate, Calcomp Scottsdale, AZ) that allowed the following variables to be measured 
[abbreviated according to Parfitt et al. (32)]: trabecular area (Tb.Ar); tissue area (T.Ar); trabecular 
perimeter (Tb.Pm); resorption perimeter (Rs.Pm); double-labeled surface (dL.Pm); single-labeled 
surface (sL.Pm); and inter label width (Ir.L.Wi). Only secondary spongiosa in the proximal tibial 
metaphysis was measured in a representative region 1 mm distal to the epiphyseal growth plate and 
extending 3 mm distally. The following indices were then calculated according to Li et al (33): 
BV/TV (Tb.Ar/T.Ar, %); trabecular width, Tb.Wi [(2000/1.199) x (Tb.Ar/Tb.Pm), µm]; trabecular 
number, Tb.N [(1.199/2) x (Tb.Pm/T.Ar), n/mm], trabecular separation, Tb.Sp [(2000/1.199) x 
(T.Ar-Tb.Ar)/Tb.Pm, µm], mineralizing surface, MS [(dL.Pm + sL.Pm/2)/Tb.Pm x 100, %], 
mineral apposition rate, MAR (Ir.L.Wi/ interval, µm/d), bone formation rate, BFR/B.Ar (MAR x 
MS/ Tb.Ar x 365 x 100, %/y); and resorption surface Rs.S (Rs.Pm/Tb.Pm x 100, %). Bone 
formation rate per unit area is considered equivalent to the rate of bone turnover (34). 
Cellular Histomorphometry 
Serial sections were cut at 5µm on a microtome (Shandon Historange, Pittsburgh, USA) and 
alternately stained with Masson’s trichrome, or tartrate resistant acid phosphatase (TRAP) 
counterstained with methyl green (0.2%). TRAP staining was used as a specific histological marker 
of osteoclasts. Since this enzyme is also expressed in other cells of the macrophage lineage and 
non-hematopoietic cell types such as selected chondrocytes (35), TRAP positive cells were 
confirmed as osteoclastic with the aid of a serial section stained with Masson’s trichrome.  
Osteoclast number (Oc.N) and trabecular perimeter (Tb.Pm) were measured in the proximal tibial 
metaphysis at a magnification of X 800 and osteoclast surface (OcS) was calculated (Oc.N/Tb.Pm, 
%).  
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Statistical analysis 
All data were analyzed using StatView (version 5.0; SAS Institute Inc., Cary, North Carolina, USA, 
1992-1999) using a two-way ANOVA and significant differences determined post-hoc using 
Fisher’s PLSD. Significance was accepted at P < 0.05. Probability levels between 0.05 and 0.1 were 
classified as marginal if the difference between means was greater than twice the SEM and non 
significant at P > 0.1. 
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RESULTS 
Confirmation of Ovariectomy 
Ovariectomy in rats was confirmed by the presence of atrophied uterine horns and a significantly 
reduced wet and dry uterine mass (P < 0.0001). On average, OVX rats had a fresh uterine mass of 
0.290 g and a dry uterine mass of 0.054g. In contrast, SHAM rats were associated with fresh and 
dry uterine masses of 0.996g and 0.170g, respectively. The mass of uteri from SHAM rats was not 
significantly different to basal control rats. Five rats displayed unusually high uterine masses and 
were excluded from further analysis.  
Bone Histomorphometry  
The pattern of bone loss observed following OVX was highly consistent with previous studies of 
similar duration (36). Ovariectomy in adult rats resulted in an almost complete ablation of 
trabecular bone in the proximal tibial metaphysis. Ninety-eight days following OVX, bone volume 
(BV/TV), Tb.Wi and Tb.N were significantly reduced (P < 0.0001) and Tb.Sp was significantly 
increased (P < 0.0001) compared to SHAM (Table 1). Indicative of an increase in bone turnover, 
bone formation rate (BFR/BS and BFR/B.Ar) (P < 0.0001), MS and MAR (P < 0.05) were also 
significantly elevated (Table 2). Relative to SHAM, resorption surface showed a biphasic response 
with a significant increase from baseline to 70 days (P < 0.05), and a decrease between 70 and 98 
days; a pattern that has previously been reported (36). At T1, OVX rats displayed a significantly 
greater OcS compared to SHAM controls (P < 0.0001), with no difference at T2 (Fig 1), when 
remodeling parameters would be approaching a new equilibrium, but on a significantly smaller 
bone volume. 
DFU Treatment 
Ninety-eight days after OVX, rats treated with DFU, the COX-2 inhibitor, maintained significantly 
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greater BV/TV than VEH controls (P < 0.001, Table 1), but lower than SHAM controls (P < 0.05). 
Trabecular width was significantly greater and Tb.Sp was significantly lower than VEH for both 
doses of DFU (P < 0.001), and not significantly different to SHAM values at T2 (P < 0.001). 
Trabecular number was significantly higher with DFU treatment compared to VEH (P < 0.05) at 
T2, but still lower than SHAM (P < 0.01). Rats treated with DFU also had lower bone formation 
rates (P < 0.0001) at T2 compared to VEH. Both doses of DFU maintained BFR/BS and BFR/B.Ar 
at SHAM levels following OVX, indicating an effective suppression of accelerated bone turnover. 
Mineralizing surface was marginally lower in rats treated with 2.0mg.kg-1 of DFU compared to 
VEH at T2 (P < 0.08). At 2.0 mg.kg-1, MAR was significantly greater than VEH at T1; but, by T2, 
MAR was significantly lower than VEH for both doses and no different to SHAM (Table 2).  
At 70 days, DFU had effectively reduced indices of bone resorption. Resorption surface was 
significantly lower in DFU groups compared to VEH (P < 0.05), and not significantly different to 
SHAM animals. Rats treated with the 2.0 mg.kg-1 DFU also had marginally lower OcS (P = 0.08) 
compared to VEH at T1. The lower dose of DFU had relatively little effect on these parameters, 
with OcS remaining significantly higher than VEH and SHAM animals (P < 0.05)(Fig 1). 
KH064 Treatment  
With the exception of OcS, the effects of DFU and KH064, the sPLA2-IIa inhibitor, on static and 
dynamic remodeling indices in the rat were very similar. When compared to VEH at 98 days, 
BV/TV was two-fold greater in rats treated with KH064 (P < 0.08); and Tb.Wi was significantly 
greater (P < 0.001), being maintained no differently to SHAM values (Table 1). KH064 at 0.4 
mg.kg-1 marginally elevated Tb.N above VEH levels, (P < 0.08), and Tb.Sp was significantly 
reduced with 4.0 mg.kg-1 of KH064 compared to VEH (P < 0.001). Although DFU and KH064 
treatment preserved a significant proportion of BV/TV and Tb.N, treatment was not sufficient to 
restore the early loss of bone that occurred during the non-treatment period post-OVX. These 
variables were maintained at levels greater than VEH groups, but less than SHAM animals, 
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implying that the loss of bone occurred soon after surgery. These early trabecular modifications 
were not improved by treatment with DFU or KH064, indicating that the COX-2 and sPLA2 
inhibitors are essentially anti-catabolic (37), being able to maintain existing trabecular architecture, 
but unable to build or improve already weakened or lost bone.  
At T1, indices of bone formation rate were significantly higher in rats treated with the 
higher dose of KH064 compared to VEH (P < 0.05). This is a manifestation of the early inhibition 
of resorptive activity by KH064, giving rise to a bone formation phase earlier than that seen in VEH 
groups. In contrast, both BFR/BS (P < 0.05) and BFR/B.Ar (P < 0.0001) were significantly lower at 
T2 with both doses of KH064 treatment, such that there was no significant difference to SHAM 
levels. Only rats treated with the higher dose of KH064 had significantly elevated MS at T1 (P < 
0.001), and MAR was significantly higher following treatment, but significantly lower at T2 when 
compared to VEH (P < 0.05)(Table 2). At both time-points, KH064 treatment maintained MAR at 
SHAM levels.  
 Compared to VEH, resorption surface was marginally lower in rats treated with the lower 
dose of KH064 (P < 0.08) and significantly reduced by the higher dose (P < 0.05) at T1 (Fig 1). In 
contrast, resorption surface was significantly higher with KH064 treatment at T2 compared to VEH 
(P < 0.001). This seemingly counter-intuitive observation is due to the almost complete ablation of 
trabecular bone in the tibial metaphysis of vehicle-treated animals. The higher BV/TV in treated 
animals continues to provide bone surfaces for remodeling, and a measurable extent of RsS. 
Compared to VEH, treatment with either dose of KH064 significantly reduced relative osteoclast 
surface at T1 (P < 0.001), with no differences observed when compared to SHAM values.   There 
was no significant treatment effect at T2. 
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Table 1: Static histomorphometric indices of bone remodeling in the proximal tibial metaphysis of adult rats 
Timepoint (Days Post-Surgery) 
0 14  70 (T1)  98 (T2)  
Baseline OVX Control  VEH Low dose High dose  VEH Low dose High dose 
BV/TV (%) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
19.50 
(2.19) 
 
 
 
 
18.10 (1.85) 
 
 
14.22 (0.99) 
5.55 (0.89)A 
 
 
 
 
7.56 (1.34) 
8.14 (2.13) 
 
 
 
8.42 (1.72) 
6.11 (0.96) 
 
 
 
 
 
16.03 (1.6) 
2.12 (0.69)A 
 
 
 
 
6.43 (1.12)AE 
6.40 (1.43)AE 
 
 
 
11.37 (1.57)AB 
6.30 (1.52)AE 
Tb.Wi (µm) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
48.10 
(1.73) 
 
 
 
 
 
42.79 (1.81) 
 
 
 
46.19 (1.19) 
43.76 (2.26) 
 
 
 
 
43.26 (1.74) 
44.27 (6.44) 
 
 
 
41.6 (1.83) 
39.49 (1.30) 
 
 
 
 
 
48.80 (2.56) 
32.06 (5.21)A 
 
 
 
 
43.75 (2.71)B 
47.92 (3.04)B 
 
 
 
51.85 (5.09)B 
48.64 (1.57)B 
Tb.N (#/mm) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
4.02 
(0.36) 
 
 
 
 
 
4.19 (0.34) 
 
 
 
3.25 (0.27) 
1.27 (0.19)A 
 
 
 
 
1.75 (0.30) 
1.61 (0.27) 
 
 
 
1.93 (0.34) 
1.52 (0.22) 
 
 
 
 
 
3.36 (0.20) 
0.52 (0.12)A 
 
 
 
 
1.47 (0.25)AB 
1.30 (0.31)AE 
 
 
 
2.16 (0.26)AB 
1.23 (0.26) 
Tb.Sp (µm) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
216.53 
(24.49) 
 
 
 
 
 
209.86 (24.23) 
 
 
 
 
284.34 (33.31) 
884.80 (128.40) 
 
 
 
 
 
720.16 (163.40)
861.69 (247.20)
 
 
 
636.47 (134.10) 
1132.74 (554.60)
 
258.56 (17.87)     
3115.07 (831.2)A 
 
 
 
 
910.19 (254.10)B 
2106.80 (1110.00) 
 
 
 
494.18 (67.95)B 
1434.99 (632.90)AB
Rs.S (%) 
SHAMC 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
10.14 
(1.24) 
 
 
 
 
 
10.27 (0.88) 
 
 
 
9.31 (1.23) 
13.69 (1.60)A 
 
 
 
 
10.40 (2.08)E 
10.39 (1.08)E 
 
 
 
10.07 (1.60)B 
9.09 (1.31)B 
 
 
 
 
 
6.84 (0.65) 
3.41 (1.27) 
 
 
 
 
5.07 (0.55) 
11.59 (1.96)AB 
 
 
 
5.58 (0.71) 
9.96 (1.42)B 
Oc.S (n/mm) 
SHAM 
OVX 
COX-2 Inhibitor 
sPLA2 Inhibitor 
3.413 
(0.645) 
 
 
 
 
 
5.126 (0.842) 
 
 
 
 
4.167 (0.708) 
7.188 (1.180)A 
 
 
 
 
 
6.536 (1.041)A 
2.675 (0.927)B 
 
 
 
4.951 (1.251)AE 
2.824 (0.778)B 
 
 
2.564 (0.595) 
1.840 (0.748) 
 
 
 
 
 
5.372 (1.720)AB 
2.869 (0.507) 
 
 
 
2.247 (0.812) 
2.552 (0.806) 
 
Values are mean (SEM) for percentage trabecular area (Tb.Ar/T.Ar), trabecular width (Tb.Wi), trabecular number (Tb.N), trabecular separation (Tb.Sp), resorption surface (Rs.S/TS) and osteoclast 
surface (Oc.S) measured in the rat proximal tibial metaphysis in sham-operated (SHAM); ovariectomised (OVX); Vehicle-treated (VEH); and in rats treated with COX-2 inhibitor (DFU, 2.0 or 
0.02mg/kg/d) or sPLA2-IIA inhibitor (KH064, 4.0 or 0.04mg/kg/d). Untreated rats were euthanized at the time of surgery (Baseline) and 14 days post-surgery (OVX Control). Treated rats were 
euthanized 70days (T1) or 98days (T2) post-surgery. AP<0.05 vs SHAM; BP<0.05 vs VEH; CP<0.01 significant change with timepoint; EP<0.08 vs VEH. 
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Table 2: Dynamic histomorphometric indices of bone remodeling in the proximal tibial metaphysis of adult rats 
 
Timepoint (Days Post-Surgery) 
0 14  70 (T1)  98 (T2)  
Baseline OVX Control  VEH Low dose High dose VEH Low dose High dose 
MS (%) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
5.94 
(0.97) 
 
 
 
3.98 (0.72)  
7.98 (1.42) 
11.97 (2.04) 
 
 
 
 
14.67 (2.92) 
11.57 (1.15) 
 
 
 
16.55 (1.96) 
26.25 (9.20)AB 
 
7.58 (1.24) 
19.41 (3.71)A 
 
 
 
 
13.89 (1.74) 
15.08 (1.53) 
 
 
 
11.06 (1.52)E 
15.60 (2.09) 
MAR (µm/d) 
SHAMC 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
1.25 
(0.08) 
 
 
 
0.7 (0.07)D  
1.06 (0.07) 
1.03 (0.06) 
 
 
 
 
1.16 (0.16) 
1.05 (0.07) 
 
 
 
1.33 (0.11)B 
1.32 (0.13)B 
 
1.11 (0.07) 
1.43 (0.19)A 
 
 
 
 
1.13 (0.11)E 
1.25 (0.14) 
 
 
 
1.07 (0.07)B 
1.14 (0.10)B 
BFR/BS (µm2/µm3/y) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
27.71 
(5.13) 
 
 
 
10.90 (2.49)  
33.50 (7.33) 
46.63 (9.55) 
 
 
 
 
73.00 (20.75) 
45.80 (6.68) 
 
 
 
84.01 (14.34) 
118.47 (30.77)AB 
 
31.44 (6.08) 
122.47 (32.75)A
 
 
 
 
59.91 (11.79)B 
68.52 (9.28)B 
 
 
 
44.65 (7.55)B 
67.58 (12.05)B 
BFR/B.Ar (%/y) 
SHAM 
OVXC 
COX-2 Inhibitor 
sPLA2 Inhibitor 
100.88 
(21.68) 
 
 
 
42.05 (8.98)  
134.58 (31.29) 
183.36 (37.98) 
 
 
 
 
306.34 (93.36) 
210.06 (48.40) 
 
 
 
360.84 (77.77) 
491.06 (107.10)AB
 
113.31 (22.32) 
 745.83 (221.3)A 
 
 
 
 
248.63 (59.99)B
250.84 (18.18)B
 
 
 
155.40 (32.64)B
238.50 (43.05)B
 
Values are mean (SEM) for mineralising surface (MS), mineral apposition rate (MAR), bone formation rate at the bone surface (BFR/BS), and bone turnover (BFR/B.Ar) measured in the rat proximal 
tibial metaphysis in sham-operated (SHAM); ovariectomised (OVX); Vehicle-treated (VEH); and in rats treated with COX-2 inhibitor (DFU, 2.0 or 0.02mg/kg/d) or sPLA2-IIA inhibitor (KH064, 4.0 or 
0.04mg/kg/d). Untreated rats were euthanized at the time of surgery (Baseline) and 14 days post-surgery (OVX Control). Treated rats were euthanized 70days (T1) or 98days (T2) post-surgery. 
AP<0.05 vs SHAM; BP<0.05 vs VEH; CP<0.01 significant change with timepoint; EP<0.08 vs VEH. 
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DISCUSSION 
Ovariectomy produces a state very similar to postmenopausal bone loss. Both states are 
associated with an increase in remodeling activation and the appearance of overactive osteoclasts, 
which contribute to an increase in the depth of resorption (36, 38). Seventy days post-OVX we 
observed significant reductions in the bone volume of the proximal tibial metaphysis, associated 
with a decrease in trabecular number and increases in resorption and osteoclast surfaces. We found 
that specific inhibitors of human COX-2 and human sPLA2-IIa enzymes effectively inhibited OVX-
induced bone loss in rats by conserving trabecular bone mass and architecture through reduced bone 
remodeling and decreased resorptive activity. These data in rats support epidemiological evidence 
for a bone sparing effect of NSAIDs in postmenopausal women (26), and reinforce the critical role 
of COX-2-dependent prostaglandins in activated states of remodeling (3). Moreover, the inhibitor 
of sPLA2-IIa significantly prevented OVX-induced rises in osteoclast number, suggesting an 
important role for sPLA2-IIa in osteoclastogenesis, independent of the COX-2 metabolic pathway.  
DFU treatment preserved approximately 58% of the trabecular bone in the proximal tibia, 
compared to the residual 10% in VEH groups. Naproxen treatment (a non-specific COX inhibitor) 
has also been shown to maintain cancellous bone volume in OVX rats at about 65% after 6 weeks 
(27). Lane et al. (27) hypothesized that Naproxen may slow the progression of estrogen-dependent 
bone loss without affecting or ameliorating the final bone mass. However, over the substantially 
longer duration of treatment herein, our study does not support that conclusion. Instead our study 
provides evidence for maintenance of trabecular mass above VEH controls with COX-2 inhibition 
at 98 days post-OVX. The reduction of both formation and resorption indices at this time, and the 
return of bone formation rate to SHAM control levels, indicates that the period of rapid bone loss 
has ended and a new steady state of bone mass has been achieved. This signifies that while 
treatment continues, the preservation of trabecular architecture with DFU treatment will be retained. 
  17
The arrangement of the trabecular struts and their contiguity is more important than 
trabecular volume or density in determining the stiffness of trabecular bone (39-41), suggesting that 
structural stiffness is spatially dependent. An increase in both connectivity and mass increases 
trabecular strength more effectively than an increase in trabecular thickness alone (40, 41). 
Therefore, even though DFU and KH064 treatment could not restore the early loss of bone, 
maintenance of trabecular width and separation indicates preservation of connectivity, which is 
more important than mass conservation in determining the strength of the bone (39, 42). For 
example, when matched for age, sex, race, menopausal status and bone volume, postmenopausal 
patients with fracture have significantly lower trabecular plate density but significantly higher 
trabecular thickness compared to those without fracture (43). Hence, the structural integrity of the 
cancellous bone may become rapidly compromised when bone volume falls below a critical value 
(42). Therefore the effect of DFU and KH064 in preventing structural dissolution may decrease the 
risk of fracture by conserving the structural strength of the trabecular bone matrix. 
In rats treated with the human sPLA2-IIa inhibitor, trabecular number and trabecular 
separation showed only small improvements above VEH rats, whilst COX-2 inhibition resulted in a 
significantly higher Tb.N compared to VEH and Tb.Sp was maintained at SHAM levels. These 
small differences between rats treated with DFU and KH064 may be explained by the redundancy 
of sPLA2-IIa. Surprisingly sPLA2-IIa knockout mice display no abnormality in inflammatory 
function, suggesting that other PLA2 classes and subtypes may compensate for the lack of sPLA2-
IIa, at least in the mouse (44). When osteoblastic cells are stimulated by TNF-α and ET-1, for 
example, other phospholipases (such as PLC and PLD) can also liberate AA independent of PKC 
activation (45-47). While cytosolic PLA2 inhibitors and COX-2 inhibitors completely abolish PGE2 
production induced by IL-1α in osteoblasts in vitro, sPLA2 inhibitors only partially affect PGE2 
synthesis in vitro (48). The multiplicity of PLA2 enzymes may account for differences in DFU and 
KH064 treatment. It is unlikely that sPLA2-IIa is the only phospholipase involved in the progression 
of OVX-induced bone loss in the rat.  
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Effect of DFU and KH064 treatment on percentage trabecular area in the proximal tibial metaphysis of the rat 
at 70 and 98 days post-OVX. Values are the mean ± SE of 8 rats. *P < 0.05, when compared with the 
respective OVX. ΔP<0.05, when compared to Sham control group. 
 
 
 
 
 
Figure 1. Effect of inhibition of COX-2 (DFU) and sPLA2-IIa (KH064) on OVX-induced changes in 
osteoclast surface (Oc.N/Tb.Pm) in the proximal tibial metaphysis of the adult rat, 70 (T1) and 90 (T2) 
days post-surgery. Osteoclast number (Oc.N) was determined by TRAP and Masson's Trichrome staining.  
Rats were either sham-operated and treated with vehicle (SHAM); or ovariectomized and administered 
vehicle (VEH), DFU 0.02mg/kg/ml (DFU[0.02]) and 2.0mg/kg/ml (DFU[2.0]), or KH064 at 0.4mg/kg/ml 
(KH064[0.4]) and 4.0mg/kg/ml (KH064[4.0]). Values are the mean ± SE of 8 rats. **P<0.05 and *P<0.08, 
when compared to VEH.  ∆P<0.05, when compared to SHAM. 
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Both doses of KH064 were associated with a significantly reduced osteoclast surface; 
whereas DFU failed to effect a significant change. Because sPLA2 is upstream of COX, it may play 
a more important hierarchical role in osteoclastogenesis in vivo than COX-2. Unlike sPLA2, COX-2 
does not act directly as a trans-cellular signal, and its activity is limited to the cells in which it is 
expressed. The observed decrease in resorption surface, despite little change in osteoclast number 
with DFU, is consistent with the inhibition of COX-2 in mature osteoclasts, but a relatively smaller 
effect on osteoclastogenesis. Therefore, the modulation in osteoclast numbers following OVX may 
be the result of the action of leukotrienes and/or PAF that do not require COX activity for synthesis. 
The effectiveness of the sPLA2 inhibitor in producing a complete blockade of OVX-induced 
increases in relative osteoclast number may be explained by the relationship between 
phospholipases, leukotrienes and PAF. Both leukotrienes (49) and PAF (50) have demonstrated 
resorptive activity and could be responsible for the change in osteoclast function following OVX. 
The inhibition of sPLA2 may have reduced the substrate requirements for leukotriene and PAF 
synthesis, resulting in a decrease in OVX-associated resorptive activity. In contrast to COX-2, 
sPLA2 is important in both PG and leukotriene metabolism, with AA acting as the common 
substrate. COX-2 inhibitors have the limited capacity of affecting the PG biosynthesis pathway 
only, whilst sPLA2 inhibitors can modulate PG, leukotriene and lysophospholipid metabolism. The 
inhibition of leukotriene production by KH064 may account for reduced osteoclast numbers 
following OVX, in contrast to the limited effect of DFU treatment. 
In conclusion, treatment with inhibitors of human COX-2, or human sPLA2-IIa, maintain 
trabecular integrity and reduce bone turnover in rats to prevent the deterioration in bone architecture 
associated with estrogen loss. DFU and KH064 were effective inhibitors of OVX-induced bone loss 
in rats by conserving trabecular bone mass and architecture by maintaining interconnectivity 
through reduced bone remodeling and decreased resorptive activity. These data support 
epidemiological evidence in humans for a bone sparing effect of COX-2 inhibition under conditions 
of increased bone turnover related to aging or estrogen loss. In contrast to DFU, KH064 
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significantly prevented OVX-induced rises in osteoclast number in rats, which suggests that sPLA2-
IIa has an important role in osteoclastogenesis, one that is not dependent on the COX-2 metabolic 
pathway. Through inhibition of prostaglandin, leukotriene and possibly the PAF signaling 
pathways, sPLA2 inhibition can prevent rises in osteoclast activity resulting in a significant 
maintenance of trabecular architecture in the proximal tibial metaphysis of the rat following 
estrogen removal. These results may be important in dissecting the roles of individual eicosanoids 
in the maintenance and remodeling of human bone. 
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